# Katerina Politi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/katerina-politi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,772 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 55 |
| i10-index | 106 |
| Last Known Institution | Yale Cancer Center |
| OpenAlex ID | https://openalex.org/A5067248479 |
| ORCID iD | https://orcid.org/0000-0001-6064-4527 |
| Works | 630 |

## Researcher papers

- [EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib](https://scholariq.org/papers/egf-receptor-gene-mutations-are-common-in-lung-cancers-from-never-smokers-and/)
- [Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain](https://scholariq.org/papers/acquired-resistance-of-lung-adenocarcinomas-to-gefitinib-or-erlotinib-is/)
- [Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer](https://scholariq.org/papers/impaired-hla-class-i-antigen-processing-and-presentation-as-a-mechanism-of/)
- [Cycling cancer persister cells arise from lineages with distinct programs](https://scholariq.org/papers/cycling-cancer-persister-cells-arise-from-lineages-with-distinct-programs/)
- [Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA](https://scholariq.org/papers/early-assessment-of-lung-cancer-immunotherapy-response-via-circulating-tumor-dna/)
- [EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer](https://scholariq.org/papers/egfr-mutation-subtypes-and-response-to-immune-checkpoint-blockade-treatment-in/)
- [Reduced <i>NF1</i> Expression Confers Resistance to EGFR Inhibition in Lung Cancer](https://scholariq.org/papers/reduced-i-nf1-i-expression-confers-resistance-to-egfr-inhibition-in-lung-cancer/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Researcher university

- [Yale Cancer Center](https://scholariq.org/institutions/yale-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.